This inventor holds 3 USPTO granted patents. Top assignees: Wyeth, American Home Products Corporation. Active years: 2001-2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001-2002
Title: The Innovations of John U Lamer
Introduction
John U Lamer is a notable inventor based in St. Albans, VT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of extended release formulations. With a total of 3 patents to his name, Lamer's work has had a meaningful impact on medication delivery systems.
Latest Patents
One of Lamer's latest patents is an extended release formulation of venlafaxine hydrochloride. This invention relates to a 24-hour extended release dosage formulation and unit dosage form of venlafaxine hydrochloride, an antidepressant. It provides better control of blood plasma levels compared to conventional tablet formulations, which require administration two or more times a day. Additionally, it offers a lower incidence of nausea and vomiting than traditional tablets. The formulation comprises a therapeutically effective amount of venlafaxine hydrochloride in spheroids made of venlafaxine hydrochloride, microcrystalline cellulose, and optionally, hydroxypropylmethylcellulose, coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
Career Highlights
Throughout his career, John U Lamer has worked with prominent companies such as Wyeth and American Home Products Corporation. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
Lamer has collaborated with notable coworkers, including Deborah M Sherman and John C Clark. These partnerships have likely enhanced his research and development efforts in the pharmaceutical field.
Conclusion
John U Lamer's contributions to the development of extended release formulations have significantly advanced the field of pharmaceuticals. His innovative work continues to influence medication delivery systems, improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
